National Cancer Institute (NCI): Neoplasms trials

The registry lists 318 Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 27 are open to participants now and 76 have results posted.

Early Phase 1 3Phase 1 178Phase 2 89Phase 3 2No phase 66(a study in two phases counts in both)

Studies

Page 2 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Vaccine and Chemotherapy for Previously Untreated Metastatic Breast CancerTerminatedNCT00048893Phase 1/2Results posted
• EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionCompletedNCT00006436Phase 2Results posted
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and ChemotherapyCompletedNCT00004547Phase 2Results posted
• Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced CancerWithdrawnNCT07484282
• Experience and Management of Cancer Screening-Related Anxiety in Fanconi AnemiaActive, not recruitingNCT06744283
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnNCT06161558Phase 1
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 2
• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingNCT05256225Phase 3
• Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedNCT04847466Phase 2
• Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)CompletedNCT04774289
• NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 DataActive, not recruitingNCT04750915
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)sTerminatedNCT04488263
• Mobile Sensor Technologies to Assess General Symptomology of People With CancerCompletedNCT04465214
• Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainCompletedNCT04442425
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial NeoplasiaWithdrawnNCT04411134Phase 1
• M7824 Related Adverse Effects in Adults With CancerActive, not recruitingNCT04267861
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
• Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsTerminatedNCT03189108
• The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk TradeoffsWithdrawnNCT02874053
• Natural History of and Specimen Banking for People With Tumors of the Central Nervous SystemCompletedNCT02851706
• Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary MetastasectomyWithdrawnNCT02839694Phase 1
• Collection of Tissue Blocks or Slides From Patients With CancerCompletedNCT02810405
• Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear TestCompletedNCT02734303
• Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer PatientsTerminatedNCT02706652
• Biomarker Analysis of Central Nervous System TumorsTerminatedNCT02692898
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid TumorsCompletedNCT02423057Phase 1
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1
• Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedNCT02379416Phase 1
• Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced CancerCompletedNCT02317874Phase 1
• Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to TreatmentActive, not recruitingNCT02243592
• Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With CancerCompletedNCT02108028
• Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic DysfunctionCompletedNCT02070549Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnNCT01679743Phase 2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
• Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System TumorsCompletedNCT01538095Phase 1
• FdCyd and THU for Advanced Solid TumorsCompletedNCT01534598Phase 1
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerTerminatedNCT01457131Phase 1
• Dasatinib in Combination With Bevacizumab to Treat Advanced Solid TumorsCompletedNCT01445509Phase 1
• Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain MetastasesCompletedNCT01445483
• A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid TumorsCompletedNCT01445106Phase 1
• NHS-IL12 for Solid TumorsCompletedNCT01417546Phase 1
• Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalTerminatedNCT01341496Phase 1
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
• AZD6244 With Cetuximab for Solid Tumors and Colorectal CancerCompletedNCT01287130Phase 1
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain TumorsCompletedNCT01259479Phase 1
• AT13387 in Adults With Refractory Solid TumorsCompletedNCT01246102Phase 1
• Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid TumorsCompletedNCT01240538Phase 1
• 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid TumorsCompletedNCT01191216Phase 1
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01141244Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Selumetinib and Cixutumumab in Treating Patients With Advanced Solid MalignanciesCompletedNCT01061749Phase 1
• A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompletedNCT01051635Phase 1
• Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum TherapyCompletedNCT01039155Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentCompletedNCT00929903Phase 1
• Pharmacokinetic Studies Participation SurveyCompletedNCT00923468
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to TreatmentCompletedNCT00880282Phase 1
• Community Cancer Centers Pilot Patient SurveyCompletedNCT00786656
• Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic CancerCompletedNCT00678769Phase 1
• AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor CancersCompletedNCT00678132Phase 1
• Aflibercept in Treating Young Patients With Relapsed or Refractory Solid TumorsCompletedNCT00622414Phase 1
• IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid TumorCompletedNCT00609141Phase 1
• Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT00576654Phase 1
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
• Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsStatus unknownNCT00454376
• Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi DeltaCompletedNCT00443313
• Human Papillomavirus (HPV) and Risk of Cervical Precancer and CancerCompletedNCT00435214
• Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00415324Phase 1
• Cancer Risk in X-Ray Technologists: Second SurveyCompletedNCT00410475
• Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00408655Phase 1
• 3-AP in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT00390052Phase 1
• Sunitinib in Treating Young Patients With Refractory Solid TumorsCompletedNCT00387920Phase 1
• AFP464 in Treating Patients With Advanced Solid TumorsTerminatedNCT00369200Phase 1
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• Agriculture Health StudyActive, not recruitingNCT00352924
• Case-Control Study of Pesticides and Childhood LeukemiaCompletedNCT00342888
• Nutrition Intervention Trials in Linxian Follow-up StudyCompletedNCT00342654
• Costa Rican Natural History Study of HPV and Cervical NeoplasiaTerminatedNCT00342173
• The Second Multicenter Hemophilia Cohort StudyCompletedNCT00341705
• Studying Normal Breast Tissue and Cancer RiskCompletedNCT00341692